Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)

Carbonell, Cristina ; Marcos, Miguel ; Guillén-del-Castillo, Alfredo ; Rubio-Rivas, Manuel ; Argibay, Ana ; Marín-Ballvé, Adela ; Rodríguez-Pintó, Ignasi ; Baldà-Masmiquel, Maria ; Callejas-Moraga, Eduardo ; Colunga, Dolores ; Sáez-Comet, Luis (Universidad de Zaragoza) ; González-Echávarri, Cristina ; Ortego-Centeno, Norberto ; Marí-Alfonso, Begoña ; Vargas-Hitos, José-Antonio ; Todolí-Parra, José-Antonio ; Trapiella, Luis ; Herranz-Marín, María-Teresa ; Freire, Mayka ; Castro-Salomó, Antoni ; Perales-Fraile, Isabel ; Madroñero-Vuelta, Ana-Belén ; Sánchez-García, María-Esther ; Ruiz-Muñoz, Manuel ; González-García, Andrés ; Sánchez-Redondo, Jorge ; de-la-Red-Bellvis, Gloria ; Fernández-Luque, Alejandra ; Muela-Molinero, Alberto ; Lledó, Gema-María ; Tolosa-Vilella, Carles ; Fonollosa-Pla, Vicent ; Chamorro, Antonio-Javier ; Simeón-Aznar, Carmen-Pilar

Resumen: Aim

Patients with systemic sclerosis (SSc) are at increased risk of cancer, a growing cause of non–SSc-related death among these patients. We analyzed the increased cancer risk among Spanish patients with SSc using standardized incidence ratios (SIRs) and identified independent cancer risk factors in this population.

Material and methods

Spanish Scleroderma Registry data were analyzed to determine the demographic characteristics of patients with SSc, and logistic regression was used to identify cancer risk factors. SIRs with 95% confidence intervals (CIs) relative to the general Spanish population were calculated.

Results

Of 1930 patients with SSc, 206 had cancer, most commonly breast, lung, hematological, and colorectal cancers. Patients with SSc had increased risks of overall cancer (SIR 1.48, 95% CI 1.36–1.60; P < 0.001), and of lung (SIR 2.22, 95% CI 1.77–2.73; P < 0.001), breast (SIR 1.31, 95% CI 1.10–1.54; P = 0.003), and hematological (SIR 2.03, 95% CI 1.52–2.62; P < 0.001) cancers. Cancer was associated with older age at SSc onset (odds ratio [OR] 1.22, 95% CI 1.01–1.03; P < 0.001), the presence of primary biliary cholangitis (OR 2.35, 95% CI 1.18–4.68; P = 0.015) and forced vital capacity <70% (OR 1.8, 95% CI 1.24–2.70; P = 0.002). The presence of anticentromere antibodies lowered the risk of cancer (OR 0.66, 95% CI 0.45–0.97; P = 0.036).

Conclusions

Spanish patients with SSc had an increased cancer risk compared with the general population. Some characteristics, including specific autoantibodies, may be related to this increased risk.

Idioma: Inglés

DOI: 10.1016/j.autrev.2022.103167

Año: 2022

Publicado en: AUTOIMMUNITY REVIEWS 21, 10 (2022), 103167 [10 pp.]
ISSN: 1568-9972

Factor impacto JCR: 13.6 (2022)

Categ. JCR: IMMUNOLOGY rank: 12 / 161 = 0.075 (2022) - Q1 - T1

Factor impacto CITESCORE: 23.3 - Immunology and Microbiology (Q1) - Medicine (Q1)

Factor impacto SCIMAGO: 2.552 - Immunology and Allergy (Q1) - Immunology (Q1)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)